PTC Therapeutics, Inc.
PTCT
$73.46
-$1.56-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 272.55M | 164.68M | 211.01M | 178.88M | 1.18B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 272.55M | 164.68M | 211.01M | 178.88M | 1.18B |
| Cost of Revenue | 39.16M | 140.08M | 115.94M | 124.41M | 21.53M |
| Gross Profit | 233.39M | 24.60M | 95.07M | 54.47M | 1.15B |
| SG&A Expenses | 86.18M | 96.87M | 84.05M | 85.26M | 80.96M |
| Depreciation & Amortization | 11.58M | 9.35M | 7.53M | 4.06M | 3.80M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 226.67M | 246.30M | 207.52M | 213.73M | 206.59M |
| Operating Income | 45.89M | -81.62M | 3.49M | -34.86M | 969.50M |
| Income Before Tax | -2.46M | -139.08M | -23.07M | -71.05M | 929.83M |
| Income Tax Expenses | 347.00K | -4.12M | -38.97M | -6.20M | 63.27M |
| Earnings from Continuing Operations | -2.81M | -134.97M | 15.90M | -64.85M | 866.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.81M | -134.97M | 15.90M | -64.85M | 866.56M |
| EBIT | 45.89M | -81.62M | 3.49M | -34.86M | 969.50M |
| EBITDA | 61.30M | -68.72M | 14.60M | -27.28M | 976.72M |
| EPS Basic | -0.03 | -1.67 | 0.20 | -0.83 | 11.09 |
| Normalized Basic EPS | -0.02 | -1.16 | -0.25 | -0.57 | 7.45 |
| EPS Diluted | -0.03 | -1.67 | 0.20 | -0.83 | 10.04 |
| Normalized Diluted EPS | -0.02 | -1.16 | -0.23 | -0.57 | 6.74 |
| Average Basic Shares Outstanding | 82.52M | 80.69M | 78.47M | 78.15M | 78.12M |
| Average Diluted Shares Outstanding | 82.52M | 80.69M | 87.12M | 78.15M | 86.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |